3Seung KJ,Bai GH,Kim SJ,et al.The treatment of tuberculosis in south Korea.Int J Tuberc Lung Dis,2003,7:912-919.
4Center for Disease Control and Prevention.TB elimination:now is the time.2002.Available from:URL:http://www.cdcnpin.org/scripts/tb/eliminate.asp.
5Ashokraj Y,Agrawal S,Varma MV,et al.Quality control of antituberculosis fixed-dose combination formulations in the global market:an in vitro study.Int J Tuberc Lung Dis,2004,8:1081-1088.
6Sterling TR,Lehmann HP,Frieden TR.Impact of DOTS compare with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths:decision analysis.BM J,2003,326:574.
7World Health Organization.Guidelines for the programmatic management of drug-resistant tuberculosis.Geneva:WHO,2006.361.
8Coninx R, Mathieu C, Debacker M, et al. First-line tuberculosis therapy and drug-resistant Mycobacterium tuberculosis in prisons. Lancet, 1999,20,353:969-973.
9Scrim T, Atac G, Gungor G, et al. Treatment outcome of relapse and defaulter pulmonary tuberculosis patients. Int J Tuberc Lung Dis ,2002,6:320-325.
10Kritski AL, Rodrigucs de Jesus LS, Andradc MK, et al. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes Chest, 1997,111 : 1162-1167.
